GSK prepares to cash in on bird flu fears
Wednesday 19 October 2005
The company is hoping to benefit from the contingency plans of worried governments and corporations, as Roche, its Swiss rival, struggles to keep up with demand for Tamiflu, its flu treatment and the most widely regarded means of treating any outbreak of avian flu.
The Swiss company is likely to say today that it has witnessed a significant upswing in orders for Tamiflu, as it reports its latest quarterly results. It received US approval yesterday for a new Tamiflu manufacturing plant but was having to bat away growing calls for the company to give up patents and allow other pharmaceuticals companies to make the pills.
GSK's Relenza acts in a similar way to help fight the flu virus but is regarded as less reliable because it is inhaled, not swallowed. That might mean people with breathing difficulties do not get the correct dose.
Many governments are likely to resist calls to stockpile GSK's drug because of this drawback and because neither drug is wholly effective, only lessening the symptoms if taken early enough. The UK Government is buying 14.6 million doses of Tamiflu, enough to treat a quarter of the population.
GSK said it was enjoying significant interest in Relenza and was talking to several governments about contributing to bird flu stockpiles. One City analyst said the company might see an additional $1.4bn (£800m) in annual sales of the drug when the new capacity comes on-stream.
The company made 11 million doses of Relenza last year and has invested in new equipment at several manufacturing sites, including at Montrose in Scotland, that will boost capacity to 31 million doses in 2007, with more to follow.
Michael Leacock, a drug sector analyst at Nomura, told clients: "A major opportunity lies in the US, where the joint National Vaccination Advisory Committee and Advisory Committee for Immunization Practices meeting recommended that 133 million treatments of flu drugs be stockpiled in preparation for a possible pandemic. We understand Roche can deliver only 10 million courses of its Tamiflu in 2005 and 12 million in 2006 to the US, despite its new US plant. Relenza is seen as an important back-up product in pandemic flu planning."
Shares in Roche were among the best performers on the Swiss stock exchange yesterday because of investor excitement over Tamiflu, but there are increasing calls for it to give up its monopoly on the product.
Cipla, India's second-largest drug maker, will put in a provocative request today for a licence to make Tamiflu. Several US politicians have demanded Roche allow US companies to set up manufacturing plants.
- 1 Tamir Rice: 12-year-old boy playing with fake gun dies after being shot by police in Ohio park
- 3 Naked free runner captured in breathtaking photographs above London's streets
- 4 Woman opens professional cuddling shop – gets 10,000 customers in first week
Tamir Rice: 12-year-old boy playing with fake gun dies after being shot by police in Ohio park
Heroin to be prescribed to Canadian addicts by doctors
Audacious North Korean kidnap plot foiled at Paris airport as 'Asian men' attempted to bundle student onto plane
Tower Bridge glass walkway 'smashed' by night-time visitor dropping bottle of beer
Revealed: the case against Bill Cosby – through the stories of his accusers
Rochester by-election: Ukip gains second MP as Tory defector Mark Reckless holds seat
'Beast of Bolsover' Dennis Skinner takes Ukip MP Mark Reckless to task moments after he is sworn in
Rochester by-election: Labour MP Emily Thornberry resigns after posting white van and England flags tweet
The young are the new poor: Sharp increase in number of under-25s living in poverty, while over-65s are better off than ever
France 'blocks' Russian sailors from boarding a warship
Green Party Caroline Lucas interview: 'We could be on the edge of something very big'
iJobs Money & Business
Negotiable: Argyll Scott International: Hi All, I'm currently recruiting for t...
£50000 - £60000 per annum + benefits: Argyll Scott International: A Business A...
£30000 - £35000 per annum + benefits: Ashdown Group: PR Marketing & Events Exe...
$80000 - $110000 per annum, Benefits: Bonus and Employee Investment Scheme: Se...